Previous 10 | Next 10 |
The following slide deck was published by Cyclo Therapeutics, Inc. in conjunction with this event. For further details see: Cyclo Therapeutics (CYTH) Investor Presentation - Slideshow
– Live video webcast with moderated fireside chat with members from the Cyclo Therapeutics management team and featuring Key Opinion Leader, Cynthia A. Lemere, PhD on Tuesday, April 5 th at 1:00 PM ET Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Ther...
– Collaboration with the University of the Witwatersrand, Johannesburg (“Wits”), represented by Wits Commercial Enterprise; a wholly-owned subsidiary of the University mandated to manage and commercialize the University’s Intellectual Property; expected to ...
- Live webcast fireside chat on Wednesday, March 30 th at 12:30 PM ET Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines t...
Cyclo Therapeutics press release (NASDAQ:CYTH): FY GAAP EPS of -$2.24 misses by $0.36. Revenue of $1.58M (+75.6% Y/Y) misses by $0.48M. For further details see: Cyclo Therapeutics GAAP EPS of -$2.24 misses by $0.36, revenue of $1.58M misses by $0.48M
- Lead development program evaluating Trappsol ® Cyclo™ for Niemann-Pick Disease Type C1 (NPC1) in ongoing pivotal study (TransportNPC™) continues to progress - Company advancing Trappsol ® Cyclo™ for the treatment of Alzheimer’s D...
Presentation with live video webcast on Wednesday, March 16 th at 3:20 PM ET Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medi...
Because many receptors and factors lead to the onset and early progression of Alzheimer's disease, targeting any one of them only slightly slows down the progression of Alzheimer's in subgroups. Targeting intervening points between receptor overactivation and peroxynitrite formation, ...
Most treatments for Alzheimer's disease either lead to only temporary improvements in cognition or only minimally slow down the progression of the disease because they only inhibit peroxynitrite formation. Anavex 2-73 appears to almost stabilize Alzheimer's disease for long periods of...
Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today an...
News, Short Squeeze, Breakout and More Instantly...
Cyclo Therapeutics Inc. Company Name:
CYTH Stock Symbol:
NASDAQ Market:
Cyclo Therapeutics Inc. Website:
Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that...
Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that...
NEWARK, N.J., June 14, 2024 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL), today reported its financial results for the third quarter and the first nine months of fiscal 2024 ended April 30, 2024. “During fiscal 2024, we have continued to develop our existing portfolio while ...